Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

by Anna May Suidan, Laila Roisman, Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Alona Zer, Nir Peled
Published 2019-05-01

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

by Stephen V Liu, Elizabeth Dudnik, Mor Moskovitz, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Ofer Rotem, Mira Wollner
Published 2021-02-01

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

by Elizabeth Dudnik, Elizabeth Dudnik, Jair Bar, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Julia Dudnik, Tzippy Shochat, Aaron M. Allen, Aaron M. Allen, Alona Zer, Alona Zer, Ofer Rotem, Nir Peled, Nir Peled, Damien Urban, Damien Urban
Published 2021-03-01

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

by Michal Sternschuss, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer
Published 2020-08-01

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

by Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem, Elizabeth Dudnik, Alona Zer, Aaron M. Allen
Published 2021-01-01

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

by Omer Gal, Elizabeth Dudnik, Ofer Rotem, Inbar Finkel, Idit Peretz, Alona Zer, Jacob Mandel, Alexandra Amiel, Tali Siegal, Jair Bar, Anastasiya Lobachov, Shlomit Yust
Published 2020-01-01

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

by Sameh Daher, Yaacov R. Lawrence, Elizabeth Dudnik, Ekaterina Hanovich, Damien Urban, Nir Peled, Rossie Navon, Raya Leibowitz, Ariel Hammerman, Erez Battat, Teodor Gottfried, Amir Onn, Jair Bar
Published 2021-07-01

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da...

by Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, On behalf of the Israel Lung Cancer Group
Published 2021-01-01